KeyCorp Has Lowered Expectations for Phreesia (NYSE:PHR) Stock Price

Phreesia (NYSE:PHR - Get Free Report) had its target price reduced by stock analysts at KeyCorp from $30.00 to $28.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. KeyCorp's price objective points to a potential upside of 21.53% from the company's previous close.

Several other equities research analysts also recently weighed in on PHR. Citigroup raised their price objective on Phreesia from $31.00 to $35.00 and gave the company a "buy" rating in a report on Friday, January 10th. Royal Bank of Canada upgraded Phreesia from a "sector perform" rating to an "outperform" rating and boosted their price target for the stock from $24.00 to $32.00 in a report on Wednesday, January 8th. Piper Sandler reiterated an "overweight" rating and issued a $33.00 price objective (up previously from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Canaccord Genuity Group boosted their target price on shares of Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. Finally, DA Davidson dropped their price target on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat, Phreesia presently has an average rating of "Buy" and a consensus price target of $31.33.

Phreesia Price Performance

PHR traded down $0.93 on Wednesday, hitting $23.04. 127,591 shares of the stock were exchanged, compared to its average volume of 432,819. The business has a 50-day moving average of $26.07 and a two-hundred day moving average of $24.32. Phreesia has a 12 month low of $17.07 and a 12 month high of $30.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -15.67 and a beta of 0.82.

Insider Buying and Selling at Phreesia

In related news, General Counsel Allison C. Hoffman sold 1,213 shares of Phreesia stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $23.81, for a total value of $28,881.53. Following the completion of the sale, the general counsel now owns 137,921 shares of the company's stock, valued at approximately $3,283,899.01. This trade represents a 0.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Evan Roberts sold 3,519 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $30.06, for a total transaction of $105,781.14. Following the transaction, the chief operating officer now owns 741,197 shares in the company, valued at approximately $22,280,381.82. The trade was a 0.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 177,526 shares of company stock valued at $4,908,117. Company insiders own 5.80% of the company's stock.

Institutional Trading of Phreesia

Several institutional investors and hedge funds have recently made changes to their positions in PHR. QRG Capital Management Inc. lifted its holdings in Phreesia by 8.0% during the first quarter. QRG Capital Management Inc. now owns 11,118 shares of the company's stock worth $284,000 after acquiring an additional 827 shares during the period. SG Americas Securities LLC purchased a new position in Phreesia during the 1st quarter valued at about $462,000. Rhumbline Advisers lifted its stake in Phreesia by 3.8% in the 1st quarter. Rhumbline Advisers now owns 86,844 shares of the company's stock worth $2,220,000 after purchasing an additional 3,213 shares in the last quarter. GAMMA Investing LLC boosted its stake in Phreesia by 10,605.7% during the first quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock valued at $145,000 after buying an additional 5,621 shares during the period. Finally, Probity Advisors Inc. purchased a new position in shares of Phreesia during the fourth quarter worth about $304,000. Hedge funds and other institutional investors own 92.10% of the company's stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.